Search results
Showing 511 to 525 of 973 results for death
Evidence-based recommendations on eribulin (Halaven) for locally advanced or metastatic (secondary) breast cancer in adults who have had 2 or more courses of chemotherapy.
Evidence-based recommendations on pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer in adults.
Avelumab for untreated metastatic Merkel cell carcinoma (TA691)
Evidence-based recommendations on avelumab (Bavencio) for untreated metastatic Merkel cell carcinoma in adults.
Show all sections
Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)
Evidence-based recommendations on dapagliflozin (Forxiga) given with 2 other drugs for treating type 2 diabetes in adults.
being more aware of the likely progression and prepare themselves for the death of their loved one.Accurate predictions of survival...
the person's place of residence, such as a nursing home, especially when death is imminent. Such discharges are often delayed because of...
coagulopathy could reduce mortality from haemorrhage, which is the main cause of death in patients with major trauma. Point-of-care...
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)
Evidence-based recommendations on momelotinib (Omjjara) for treating myelofibrosis-related splenomegaly or symptoms in adults.
impact of anticipatory prescribing on outcomes such as preferred place of death and symptom control, and also uncertainty as to what...
individually and collectively, as predictors for physical harm (including death). Source guidance details Comes from guidance Eating...
This guideline covers organising and delivering end of life care services, which provide care and support in the final weeks and months of life (or for some conditions, years), and the planning and preparation for this. It aims to ensure that people have access to the care that they want and need in all care settings. It also includes advice on services for carers.
This document summarises the most common accessibility changes NICE is making in guidelines, and why
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy.
Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)
Evidence-based recommendations on mexiletine (Namuscla) for treating the symptoms of myotonia in adults with non-dystrophic myotonic disorders.
Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults.